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Abstract
Unsolved riddle of cancer remains a major global health concern particularly
in hepatocellular carcinoma (HCC) which is among the leading causes of cancerrelated death worldwide. Saffron (Crocus sativus L.) and its bioactive phytochemicals
possess promising anti-cancer activities. One of these phytochemicals, safranal, has
demonstrated potent anti-cancer activities against different types of cancers. Yet, its
association with liver cancer remains under documented. This study investigated HCC
response to safranal’s treatment via transcriptomic approach. Safranal was found to be
involved in mitochondrial dysfunction, induced oxidative stress and increased reactive
oxygen species (ROS) production leading to cell death. Interestingly, safranal has
seemingly interfered with mitogen-activated protein kinase (MAPK) signaling
pathway that is responsible for cell growth, proliferation, differentiation and survival.
Through ingenuity pathway analysis (IPA), 45 genes were associated with HCC
inhibition. To further pinpoint specific genes, IPA re-analysis revealed 8 genes to be
associated with decrease in tumor’s incidence and angiogenesity. Taken together, this
study unravel safranal’s novel potential as a natural therapeutic agent and a much
needed adjuvant against HCC.

Keywords: Hepatocellular carcinoma, RNA sequencing, Saffron, Safranal, Transcriptomic
analysis.
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)Title and Abstract (in Arabic

تحليل ترنسكربيتومي لنموذج سرطان الكبد طبقا إلستجابته لعالج الزعفران
الملخص

يبقى مرض السرطان ،المرض العضال ،أحد أبرز المشكالت الصحية على مستوى
العالم و ال سيما سرطان الكبد ) (HCCو الذي يعتبر من ضمن األسباب الرئيسية المرتبطة بوفيات
السرطان عالمياَ .و تستفيد هذه الدراسة من خالل الزعفران ( )Crocus sativus L.و ما يشمله من
مواد كيميائية نباتية تحمل خصائص مضادة لبعض األنشطة السرطانية .إن أحد هذه المواد
الكيميائية ( )Safranalيتمتع بخصائص مضادة عالية لمختلف أنواع السرطانات وعلى الرغم من
ذلك تبقى عالقته بسرطان الكبد محل تساؤل و تستلزم المزيد من البحث و الدراسة .و تتناول
الدراسة التي بين أيدينا استجابة سرطان الكبد )(HCC

للعالج بـ ( )Safranalمن منظور

ترانسكبتومي ).(Transciptomic
وجد أن الـ ( )Safranalتسبب في إختالل الميتوكوندريا ،و قد زاد أيضا َ من إنتاج
أنواع األكسجين التفاعلية ( )ROSمما جعله يصل إلى مرحلة يصبح فيها موت الخلية إلزامياَ .و
قد تتدخل ( )Safranalأيضا بصورة مدهشة بـ ألية ( )MAPKو هي المسؤولة عن النمو ،تكاثر،
تمايز الخلوي و بقاء الخلية على قيد الحياة.
عرف أن  45من الجينات الوراثية تمت بصلة إلحباط
و عند إجراء تحليل (ُ ، )IPA
سرطان الكبد ) ،(HCCوللمزيد من الدقة تم إعادة إجراء تحليل ( )IPAللجينات السابقة ،مما
ساعد على إيجاد  8من الجينات الوراثية التي لها عالقة بتقليل نسب حدوث السرطان و نمو
األوعية الدموية الجديدة .و بهذا ،فإن هذه الدراسة تقدم هذه الخصائص الفريدة للـ ()Safranal
كمنتج عالجي طبيعي و مادة مساعدة ضد سرطان الكبد ).(HCC
مفاهيم البحث الرئيسية :سرطان الكبد ،تقنية تسلسل الحمض النووي الرايبوزي ،الزعفران،
التحليل الترنسكربيتومي.
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Chapter 1: Introduction

1.1 Cancer
Cancer riddle remains unresolved and stubbornly lingers as major global health
concern. Cancer is a disease that is characterized by uncontrolled growth and division
of genetically unstable cells. The accumulation of genomic alterations varies among
different subpopulations of cells and accounts for the heterogeneity of cancer (Shen,
2011; Ferguson et al., 2015). The terms tumor and cancer may often be used
interchangeably, however, that is not always the case. Tumor refers to the abnormal
growth of mass and might be either benign or malignant growth. A benign tumor is an
abnormal growth confined to its original place and it can be removed surgically. A
malignant tumor is able to invade surrounding tissues and spread out to distant body
sites by means of the circulatory or lymphatic systems hence referred as metastasis
process. Only malignant tumors are denoted as cancer reinforcing the fact of their
ability to metastasize (Cooper, 2000).
Cancer cells acquire distinct 6 biological features from their normal
counterparts. These biological features were first introduced in 2000 and were defined
as hallmarks of cancer consist of sustaining proliferative signaling, evading growth
suppressors, resisting cell death, enabling replicative immortality, inducing
angiogenesis and activating invasion and metastasis. In 2011, additional 4 hallmarks
of cancer were introduced which were deregulating cellular energetics, avoiding
immune destruction, genomic instability and mutation and tumor promoting
inflammation (Hanahan and Weinberg, 2011).
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Cancer is the second leading cause of death worldwide accounting for 8.8
million deaths in 2015; that is 1 in every 6 deaths is due to cancer (World Health
Organization, 2018). Top cancer mortality were attributed to lung cancer by 1.69
million deaths, liver cancer by 788000 deaths, colorectal cancer by 774000 deaths,
stomach cancer by 754000 deaths and breast cancer by 571000 deaths. It is estimated
that in the next two decades, the number of new cases of cancer could mark a 70%
increase revealing an overwhelming cancer expansion.
According to Authority of Health of United Arab Emirates in Abu Dhabi,
cancer is the third leading cause of death accounting for total 16% deaths that comes
after road trauma injuries and cardiovascular diseases (Health Authority of Abu Dhabi,
2018). Records of around 427 death cases were documented due to cancer in 2015 with
56% male and 44% female. Top cancer mortality were attributed to lung cancer,
colorectal cancer, liver cancer, leukaemia and pancreas cancer in men.
There are almost 200 types of cancer, their classification depends on the site of
origin or the cell type originated from. Cancer is mostly classified into three large
groups. Carcinomas are malignancies of epithelial cells and are considered the most
common of human cancers such as squamous cell carcinoma, adenocarcinoma,
melanoma and basal cell carcinoma. Sarcomas are solid tumors of connective tissues,
such as muscle, bone, cartilage, and fibrous tissue and are considered rare in humans.
Lastly, leukemias and lymphomas are malignancies rose from the blood cells and
immune system cells, respectively (Cooper, 2000; Kirkham and Shepherd, 2001; Song
et al., 2015).
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1.1.1 Liver cancer
Liver is one of the vital organs that might become susceptible to cancer
development. Liver importance rise from its wide range of functions such as
metabolism, digestion, and detoxification. It is the only known human internal organ
that is capable of regeneration (Laursen, 2014). Liver cancer is found to be fairly
problematic to treat, and quite lethal in case of late diagnosis. In fact, thanks to its poor
diagnosis, liver cancer is now the second leading cause of global cancer-related death
with more prevalence in males rather than females (Torre et al., 2015). Primary liver
cancer can normally be distinguished into several different forms of cancer including
hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA); also known as Bileduct cancer, and hepatoblastoma. HCC is the most common primary liver cancer by
approximant 78% of incidence. CCA accounts for 15% of incidence while
hepatoblastoma and other various liver sarcomas and carcinomas accounts for 7% of
incidence (Laursen, 2014).
1.1.2 Hepatocellular carcinoma
Due to the wide prevalence of HCC over all other forms of liver cancer, its
aggressiveness, high rate malignancy and poor prognosis, HCC is the main contributor
to the global health burden of liver cancer (Tanaka and Arii, 2012). HCC originate
from adult hepatocytes upon genomic insult thereby dedifferentiate into precursor cells
that eventually transform into HCC cells (Sia et al., 2017). HCC is rather strongly
associated with numerous risk factors, including cirrhosis, chronic hepatitis B virus
(HBV), chronic hepatitis C virus (HCV), hepatitis D virus (HDV) infections, alcohol
abuse, nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis
(NASH) (Ghouri et al., 2017).
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Although the overall incidence of HCC varies based on etiology, ethnicity,
gender, age, and geographic region, still that does not overpower the most common
existence of fibrosis in HCC (Zhang and Friedman, 2012). In fact, around 90% of HCC
occurrence take place under cirrhosis settings (Seitz and Stickel, 2006). Hepatotropic
viruses, HBV, HCV and HDV, and their association with HCC development explains
the higher rate of HCC in certain geographical region. For instance, 10-20% of Eastern
Asia and Central Africa population are infected with HBV, the incidence of HCC is
30-120 in every 100,000 residents while in North and South America, and Europe,
where less HBV infections exist, the incidence of HCC is only 5-10 in every 100,000
residents (Simon et al., 2012). There is a close relationship almost synergistic between
the hepatotropic viruses; namely HBV and HCV infections, and alcohol intake to
increase the possibility of HCC development. Yet, even without HBV or HCV
infections, the effects of alcohol intake on HCC development was evident (Donato et
al., 2002). NAFLD is chronic liver disease with wide spectrum stretching from simple
hepatic steatosis to a more serious liver injury and inflammation recognized as NASH
(Cholankeril et al., 2017). In reality, 15-20% of patients of NAFLD have developed
NASH (Zezos and Renner, 2014). Exponential increase of HCC development due to
NASH risk factor is highly anticipated as the prevalence of NASH is expected to
escalate thanks to the growing epidemic of obesity and diabetes (Cholankeril et al.,
2017).
1.1.3 Hepatocellular carcinoma diagnoses
In general, early diagnoses dramatically enhance the survival rate of cancer
patients as the tumor mass is still restrained within the organ of origin (Kakushadze et
al, 2017). This is ineligible to HCC as the lack of clear symptoms and coexistence of

5
HCC with other related diseases often hinders the process of distinguishing and
detecting HCC. Only 25% of the total HCC patients were diagnosed within early stage
of HCC, that is when a single node of HCC is smaller than 5 cm, or three nodes of
HCC each smaller than 3 cm (Farinati et al., 2009; Tsuchiya et al., 2015). It is often
recommended for patients with liver cirrhosis or chronic liver diseases to have regular
screening tests to take advantage of early HCC diagnosis. Yet, gaining the benefit of
early HCC diagnosis is only possible if the liver function is still compensated. Sadly,
this does not work in patients having impaired liver function (Plentz and Malek, 2015).
1.1.4 Hepatocellular carcinoma treatment
Several factors should be taken into consideration when HCC therapeutic
strategies in question. These factors are tumor size and location, extrahepatic spread,
HCC stage, patient’s performance status and underlying liver function (Crissien and
Frenette, 2014). The standard curative treatments of HCC is represented by either
surgical resection or liver transplantation. Yet, those surgical managements are only
applicable for early stage HCC achieving 5 years’ survival with approximate of 50%
overall survival rates (Pang and Lam, 2014). Intermediate stage HCC might be eligible
for resection therapy as their only option for curative treatment. Other therapeutic
options can be locoregional therapy including percutaneous ethanol injection (PEI),
trans-arterial chemoembolization (TACE) and radiofrequency ablation (RFA).
Sorafenib is the first line treatment of advanced stage HCC which is also considered
as palliative treatment. Whilst, terminal stage HCC receives symptomatic treatment as
the only possible approach out there (Bruix and Sherman, 2011; Raza and Sood, 2014).
In advanced stage HCC, sorafenib (Nexavar) was the only chemotherapeutic
regimen approved by Food and Drug Administration (FDA). Most recently
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regorafenib (Stivarga) was another chemotherapeutic FDA approved as second line
treatment to be administrated to patients who have been previously treated with
sorafenib (Rimassa et al., 2017; Ziogas and Tsoulfas, 2017). Regorafenib is
structurally similar to Sorafenib but with different biochemical profile (Mirantes et al.,
2016). Sorafenib mechanism of action is expressed through its ability to inhibit
multiple molecular targets mainly kinases involved in tumor proliferation and
angiogenesis. These targets are serine-threonine kinases CRAF and BRAF involved in
RAF/MEK/ERK signaling cascade, RET, FLT-3, tyrosine kinase activity of vascular
endothelial growth factor receptors (VEGFRs) 1, 2 and 3 and platelet-derived growth
factor receptor β (PDGFR-β) (Le Grazie et al., 2017). Despite the positive effect of
sorafenib on advance stage HCC patients, the average overall survival is only
prolonged by nearly 3 months (Llovet et al., 2008). Moreover, sorafenib exhibited
some adverse effects such as skin-related toxicities, hypertension, proteinuria,
diarrhea, and cytopenias. Other serious life-threatening complications have been
witnessed as well including thromboembolism, bleeding, and bowel perforation. This
has led 20-30% of patients to discontinue sorafenib’s use (Crissien and Frenette, 2014).
In addition, the initial responses might seems promising but over time loss of efficacy
become evident which most probably due to drug resistance. Hence, new treatments
of HCC are desperately needed.
1.2 Herbal medicine
Form the ancient times and throughout mankind civilization, herbal/traditional
medicine was used on a regular basis to cure human diseases. Gradually but steadily,
modern medical practices replaced herbal medicine although the later still holds a solid
ground in many parts of the world especially the developing countries largely due to
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its cultural acceptance and less adverse effects (Rana and Rana, 2014). The therapeutic
value of a specific herb can be gained from the biologically active extracts or from the
intact plant which display drug-like properties. Thus different methodologies of
extraction, molecular characterization, standardization and some possible slight
modification on the biological active components could enhance the drug-like activity.
Within the last decade, improving extraction methods promoted herbal medicine
among the scientific communities (Ansari et al., 2012). As matter of fact, 25% of
worldwide drugs are actually derived from plants and 121 biological active extract are
in use (Rates, 2001).
1.2.1 Saffron
Saffron is the dried stigma of the plant Crocus sativus L.; a member of
Iridaceae family. The flower of C. sativa is light purple with three thread-like reddishcolored stigmas that are recognized as saffron spice and as a natural colorant. Saffron
is known as “red gold” in the producing countries such as Iran, India and Greece. It
has uphold its reputation as the most expensive cultivated spice herb in the world due
to cultivation labor, harvesting, and handling since it has to be handpicked. About
70,000 flowers are needed obtain over 200000 dried stigmas to yield enough for 500
g pure saffron (Srivastava et al., 2010; Gohari et al., 2013; Hosseinzadeh, 2014).
Saffron has been traditionally used to treat cramps, asthma and bronchospasms,
menstruation disorders, liver disease and pain. It was claimed to have a soothing and
tonifying effect on the gastrointestinal tract. Also it has been used as stimulant and
antidepressant (Schmidt et al., 2007). Recently, other medical properties have been
associated with saffron including anti-tumor effects, anti-inflammatory effects and
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cardioprotective effect (Abdullaev, 2002; Mehdizadeh et al., 2013; Amin and
Hosseinzadeh, 2015).
Around 150 volatile and non-volatile compounds are present in saffron,
however, less than 50 constituents have been identified. Among the volatiles, the main
component is safranal whilst the non-volatile component are crocins, crocetin,
picrocrocin and flavonoids (quercetin and kaempferol). Crocin structurally is glucosyl
esters of crocetin and is found to be water-soluble carotenoids that is responsible for
saffron’s characteristic red color. Picrocrocin is structurally glycoside of safranal and
is responsible for the bitter taste of the spice. Safranal is the main component of the
distilled essential oil and is a monoterpene aldehyde that is responsible for saffron’s
characteristic aroma. Safranal, crocin and crocetin are considered to be the main
constituents of saffron and are heavily investigated for their biological activates
(Pitsikas, 2016).
1.2.2 Safranal
Amongst its biological activities, safranal was found to exert potent
anticonvulsant activity (Hosseinzadeh and Sadeghnia, 2007), anti-oxidant activities
(Hosseinzadeh et al., 2005; Hosseinzadeh and Sadeghnia, 2005; Hosseinzadeh et al.,
2009), anti-inflammatory activities (Hazman and Bozkurt, 2015) and anti-tumor
activities (Shabestari and Samarghandian, 2013; Farahzad et al., 2014; Zhang et al.,
2017). The molecular basis of safranal’s profound anti-cancer effects remains unclear.
1.3 Transcriptome profiling
Transcriptome is the complete set of RNA transcripts and their quantity in a
given cell under certain developmental stage or physiological condition. Investigating
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the transcriptome may explain the functional elements of the genome and the
underlying mechanisms of development or disease (Wang et al., 2009; Yang and Kim,
2015). Transcriptome started in 1991 with a partial human transcriptome covering a
mere of 609 mRNA sequences. In 2008, two human transcriptomes consisting of
millions of transcript covering 16,000 genes. Transcriptomes of hundreds of
individuals can now be analyzed just like any other routine laboratory procedure. This
cascade of transcriptomes evolution clearly reflects the drastic development of new
transcriptome technologies (Lowe et al., 2017).
Gene expression studies at first were conducted using northern blots and
quantitative polymerase chain reaction (qPCR) both considered as low-throughput
methods allowing few number of transcripts measurement. Then, a sequence-based
technology was developed where generated expressed sequence tag (EST) libraries by
Sanger sequencing of complementary DNA (cDNA) was used in gene expression
studies, yet transcript quantification was not practical. Several tag-based methods were
also developed to yield a higher throughput and precise quantification of expression
levels such as serial analysis of gene expression (SAGE) and cap analysis gene
expression (CAGE). For high-throughput method, hybridization-based microarray
technologies could be performed but with notable limitations. For instance,
priori sequence information is required and cross-hybridization artifacts may interfere
with the correct interpretation. Methodologies described here are insensitive toward
splice isoforms and are not set to identify novel genes (Shendure, 2008; Kukurba and
Montgomery, 2015; Hrdlickova et al., 2016).
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1.3.1 RNA sequencing
RNA sequencing (RNA-seq) is high-throughput sequencing method. Unlike,
Sanger sequencing and microarray-based methods, RNA-Seq provides better coverage
and superior overview of transcriptomic dynamic nature. Not only gene expression
quantification is generated but also novel transcripts are discovered, alternatively
spliced genes are identified and allele-specific expression are detected. (Kukurba and
Montgomery, 2015).
RNA-seq standard workflow is shown in (Fig. 1). It starts with the
experimental set-up where the purpose of the study is outlined and statistical design is
taken into consideration. Tissue preparation and library generation, herein, involve
samples collection, RNA extraction and quality assessment, rRNA depletion or polyA enrichment, cDNA synthesis, library preparation, polymerase chain reaction (PCR)
reaction and library normalization. Then comes the high-throughput sequencing where
the sequencing platform is chosen, sequence coverage is decided. Then comes the
bioinformatics processing part, where critical needs should be met such as computing
resources and programing skills to aid in transcriptome reconstruction, mapping
strategy, gene expression quantification. Afterword, the biological inference involves
normalization, differential gene expression, gene function and interaction. Lastly,
experimental validation is needed where quantitative polymerase chain reaction
(qPCR) quantification becomes handy.
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Figure 1: A standard RNA-seq workflow (adapted from Wolf, 2013)
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1.4 Hypothesis to be tasted
The hypothesis of this study is considering saffron’s reputation as potent anticancer natural based product, will safranal holdup the same anti-cancer effect against
HCC? And what are some of its underlying mechanism?
1.5 Aims of the study
The overall aim of this study is to investigate safranal’s therapeutic effect on
HCC through transcriptomic approach.
The specific objectives are:
1. Transcriptomic analysis to figure out significant candidate genes involved in
HCC due to safranal treatment.
2. Verification of the result obtained from RNA seq using qPCR quantification.
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Chapter 2: Methods

2.1 In vivo Study
2.1.1 Animal
Wister male rats were obtained from the animal facility of the College of
Medicine and Health Sciences, UAEU. Animals were housed under a 12 hr light/dark
cycle at 24 – 26°C. They were maintained on standard laboratory animal diet with
food and water ad libitum. All animal studies were carried out in accordance with, and
after approval of the Animal Research Ethics Committee of the College of Medicine
and Health Sciences, UAEU (Approval No. A8-15).
2.1.2 Experimental design
The experimental protocol of HCC development was adapted and followed in
our lab as per described by DePeralta et al. (2016) and Pacheco-Rivera et al. (2016)
with some modifications and adjustments. This study was performed with an average
weighing 170 g male Wistar rats. Wistar rats were randomly divided into 8 groups
(n=6). The first 4 groups were labelled as control groups subdivided into control water
(C W), control safranal (C SF), control sorafenib (C SB) and control safranal and
sorafenib (C SF SB). Whereas the remaining 4 groups labelled as experimental groups
subdivided into HCC (H), HCC treated with safranal (H SF), HCC treated with
sorafenib (H SB) and HCC treated with both safranal and sorafenib (H SF SB).
Control groups were subjected to the following treatments: Group 1 (C W): Rats were
treated with distilled water alone throughout the experimental period. Group 2 (C SF): Rats
were administered orally 200 mg/kg of safranal 5 days a week for 3 weeks, total of 15 oral
gavage doses. This dose was selected based on a preventive study of safranal on nephrotoxicity
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(Karafakıoğlu et al., 2017). Group 3 (C SB): Rats were administered orally 10 mg/kg of
sorafenib 5 days a week for 3 weeks, total of 15 oral gavage doses. This dose was selected
based on earlier studies of sorafenib on a rat HCC model (Alsaied et al., 2014; Wang et al.,
2014; El-Ashmawy et al., 2016). Group 4 (C SF SB): Rats were administered orally both doses
of 200 mg/kg of safranal and 10 mg/kg of sorafenib 5 days a week for 3 weeks, total of 15 oral
gavage doses.

Whereas the experimental groups were subjected to the following treatments:
Group 5 (H): Rats were injected intraperitoneally with 50 mg/kg of diethylnitrosamine
(DEN) once a week for 15 week, total of 15 injections. Group 6 (H SF): Rats were
injected intraperitoneally with 50 mg/kg of DEN once a week for 15 week, total of 15
injections and then followed by orally administered 200 mg/kg of safranal 5 days a
week for 3 weeks, total of 15 oral gavage doses. Group 7 (H SB): Rats were injected
intraperitoneally with 50 mg/kg of DEN once a week for 15 week, total of 15 injections
and then followed by orally administered 10 mg/kg of sorafenib 5 days a week for 3
weeks, total of 15 oral gavage doses. Group 8 (H SF SB): Rats were injected
intraperitoneally with 50 mg/kg of DEN once a week for 15 week, total of 15 injections
and then followed by orally administered both doses of 200 mg/kg of safranal and 10
mg/kg of sorafenib 5 days a week for 3 weeks, total of 15 oral gavage doses.
At the end of experimental period and 24 hrs after the last treatment, rats
were anesthetized by mild Diethyl ether and dissected (Fig. 2). The whole liver
was removed and immediately flash frozen for further analysis. This experimental
model has been developed and HCC development has been histopathologically
confirmed and well characterized in our lab (AlMansoori ongoing MSc Thesis).
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Figure 2: Schematic illustration of the in vivo experimental design (adapted from
AlMansoori ongoing MSc Thesis)

2.2 Transcriptomic analysis
2.2.1 RNA extraction
Total RNA was extracted from flash frozen liver tissues using Maxwell 16
System along with Maxwell 16 Total RNA Purification Kit (Promega, US), according
to the manufacturer’s instructions with slight modifications. Briefly, 50 mg of liver
tissue immersed in 200 µl lysis buffer with 2 µl of β-mercaptoethanol (BME) was
mechanically homogenized until no visible tissue fragments is seen. The homogenized
sample was incubated for 10 min on ice for a complete lysis. Microcentrifuge was used
for a quick spin and the sample lysate was transferred into a new 1.5 ml
microcentrifuge tube. 167 µl of RNA dilution buffer was added to the sample lysate
along with 125 µl of a completely resuspend the clearing agent. The sample was
vortexed for 30 sec then it was placed in 70°C heat block for 3 min. After heating the
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sample was vortexed again for 30 sec and incubated for 5 min at room temperature.
After that the sample was transferred into clearing column assembly and centrifuged
at 12,000 × g for 2 min.
Afterward, the collected flowthrough from the collection tube was transferred
into first wall of maxwell 16 RNA cartridge while a plunger was placed into the last
wall of the cartridge. A 200 µl of nuclease-free water was placed in a separate elution
tube. Maxwell 16 Instrument was programmed according to the manufacturer’s
instructions. Upon the completion of the RNA purification, the elution tube was
removed from the platform and placed into magnetic elution tube rack for 10 min. the
eluted sample of total RNA was then transferred into a storage tube. Total RNA
concentration was measured using NanoDrop1000 spectrophotometer (Thermo Fisher
Scientific Inc.) while RNA quality, RNA integrity number (RIN) was verified using
Bioanalyzer 2100 and

RNA 6000 Nano chips according to the manufacturer’s

instructions (Agilent Technologies, CA). Total RNA concentration and RIN value per
sample are listed in (Table 1).

Table 1: Extracted total RNA measurement
Sample code
Conc. ng/µl RIN Sample code
Conc. ng/µl RIN
192.1
9.3
306.6
N/A*
G1 (C W) - 1
G5 (H) - 1
121.8
9.4
435.1
8.6
G1 (C W) - 2
G5 (H) - 2
191.9
9.5
199
9.1
G1 (C W) - 3
G5 (H) - 3
242.8
9.3
530.4
9.0
G2 (C SF) - 1
G6 (H SF) - 1
165.1
9.1
328.4
9.3
G2 (C SF) - 2
G6 (H SF) - 2
258.8
9.1
296.3
9.2
G2 (C SF) - 3
G6 (H SF) - 3
259.4
9.1
139.6
9.2
G3 (C SB) - 1
G7 (H SB) - 1
226.9
8.9
204.9
9.0
G3 (C SB) - 2
G7 (H SB) - 2
265.6
9.4
190.1
9.6
G3 (C SB) - 3
G7 (H SB) - 3
9.1
9.2
G4 (C SF SB) - 1 211.7
G8 (H SF SB) - 1 209.7
8.9
9.1
G4 (C SF SB) - 2 233.4
G8 (H SF SB) - 2 255.9
205.8
9.0
223.3
9.2
G4 (C SF SB) - 3
G8 (H SF SB) - 3
Note: (*) not available due to disturbance in the fast region estimated to be 9.2.
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2.2.2 RNA-seq libraries construction, sequencing and analysis
Brigham Young University DNA Sequencing Center (Provo, Utah, USA)
provided the service of library preparation and sequencing. Briefly, RNA-seq libraries
were prepared using KAPA Stranded mRNA-Seq kit Illumina Platforms (KAPA
Biosystems, US) following the manufacturer’s instructions. The kit is based on polyA mRNA enrichment. The produced libraries were quantified using a Kapa library
quantification kit Illumina Platforms (KAPA Biosystems, US) based on SYBR green
chemistry. Libraries were sequenced on an Illumina HiSeq 2500 sequencing system
(Illumina, Inc.) to a minimum of 20 million reads per sample.
Bioinformatics Core at New York University Abu Dhabi (NYUAB) have
processed the generated data through their standard RNA-seq analysis pipeline. In
short, alignments were performed using tophat2 v2.1.0 (Kim et al., 2013). Following
the tophat2 alignment stage, read counts were generated using HTseq count (Anders
et al., 2014).
2.2.3 Hierarchical cluster and principle component analyses
Both hierarchical cluster analysis principle component analysis (PCA) were
constructed by uploading the raw count into ClustVis, web tool for visualizing
clustering of multivariate data (Metsalu and Vilo, 2015).
2.2.4 Differential gene expression analysis
To generate differential expressed genes (DEGs) and their volcano plots, raw
counts were analyzed using RNA-seq 2G (http://52.90.192.24:3838/rnaseq2g/) an
online interface, user friendly, with over 25 statistical methods used to perform twogroup analysis of differential gene expression. DESeq2 statistical method was
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employed and significant genes were identified using cutoff values of false discovery
rate (FDR) < 0.05, and log 2 (fold change).Venn diagrams were constructed using
InteractiVenn, web-based tool (Heberle et al., 2015). Gene expected function was
extracted using Rat Genomic Database (RGD) (Shimoyama et al., 2015).
2.2.5 Gene ontology enrichment analysis
Gene set enrichment analysis of DEGs was performed using the Biological
Networks Gene Ontology tool (BiNGO) (Maere et al., 2005), plug-in for Cytoscape
software (Shannon et al., 2003).

BiNGO found the relevant biological process

annotations. This enrichment test is based on hypergeometric test and corrected
multiple testing using Benjamini and Hochberg FDR correction ≤ 0.05.
2.2.6 Pathway analysis
DEGs were analyzed through Ingenuity Pathway Analysis (IPA) (QIAGEN
Inc.,

https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis)

(Krämer et al., 2014). To allow more stringent analysis, the cutoff value of FDR was
set to 0.01. Core analysis were implicated with default settings, canonical pathways
and associated toxicity functions were reviewed. 45 genes that were associated with
HCC were re-analyzed (core analysis) for further toxicity function association.

2.2.7 Network analysis
Network analysis were performed using Search Tool for The Retrieval of
Interacting Genes (STRING) version 10.5 (http://string-db.org/) (Szklarczyk et al.,
2017). STRING, an online genes/proteins association database curated from literature,
high-throughput experimental data, and predicted associations from systemic genome
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comparisons. Rattus norvegicus databases were utilized to generate association
network for two sets of genes of interest that showed significant fold change in
expression.
2.2.8 qPCR quantification
Previously extracted RNA was used for cDNA synthesis corresponding to
1000 ng of total RNA using GoScript™ Reverse Transcription System (Promega US)
according to manufacturer’s instructions. Quantitative PCR reactions were performed
on an QuantStudio 5 Real-Time PCR System (Thermo scientific,US) using
GoTaq® qPCR Master Mix kit (Promega US) with gene-specific primers as per
manufacturer's protocol . Data were normalized relative to 18S rRNA gene values,
which exhibited stable expression levels between the two groups of G5 (H) and G6 (H
SF) unlike ACTB and GAPDH. Relative expression level of each gene was calculated
using 2-ΔΔCt method. All reactions were run in triplicate. The primers for the qPCR
reactions are listed in (Table 2).
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Table 2: qPCR primers sequences
Forward primer (5'→3')
CGTTGTATTCGCATCAAC
C

Reverse primer (5'→3')
AGCCATCCTCTCCAATC
C

PAWR

GCAGGACAGAAGGAACG
GAA

TGGGGCACTGATTGTG
CTTT

BMP4

GGGATCTTTACCGGCTCC
AG

TCTCCAGATGTTCTTCG
TGATGG

DNAJB9

GGGCGCACGGGTTATTAG
A

CTCTGAGGCTGACTTTG
GCA

CIDEA

TCCTCGGCTGTCTCAATG
TC

GAACCGCAGCAGACTC
CTTA

GCAATTATTCCCCATGAA
CG
AGACAGCCGCATCTTCTT
GT
AGACCTTCAACACCCCAG
C

GGCCTCACTAAACCAT
CCAA
CTTGCCGTGGGTAGAG
TCAT
GTCACGCACGATTTCCC
T

Gene
BTG1

18s
RRNA
GAPDH
ACTB

Source
Li et al., 2009
NCBI-Primer
designing tool (Ye
et al., 2012)
NCBI-Primer
designing tool (Ye
et al., 2012)
NCBI-Primer
designing tool (Ye
et al., 2012)
NCBI-Primer
designing tool (Ye
et al., 2012)
Asanoma et al.,
2011
Li et al., 2015
Wang et al., 2014
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Chapter 3: Results

3.1 Overview of gene expression profiles
Out of whole data set of 32884 sequenced genes, randomly 2400 genes were
selected to view an overall expression pattern among the different groups through
hierarchical cluster analysis (Fig. 3). This analysis displayed visibly distinguishable
patterns across the groups as it separated the experimental groups from the control
groups with a twist. Cancer induced groups/experimental groups clustered together
except for one; G5 (H) is clustered among G7 (H SB) and G8 (H SF SB) whereas G6
(H SF) is closely clustered with control groups G1 (C W) and then G3 (C SB). And
the rest of control groups are clustered together; G2 (C SF) and G (C SF SB). It might
be obvious that the experimental cluster together but based on this analysis, G6 (H SF)
is shown gene expression pattern closer to the control groups.
3.2 Principle component analysis
Principle component analysis (PCA) is another methodology used for
dimension reduction, simplifying data into 2 dimensional (2D) plot where PCA axes
emphasize data variation. The whole data set of 32884 sequenced genes was used in
this analysis (Fig. 4). Although a defined variance mostly on PC1 is shown among the
different control groups still does not overweight the variance shown between the
experimental groups. Clearly, G5 (H) is separated from the rest of the experimental
groups. Interestingly, both G7 (H SB) and G8 (H SF SB) are located closely to each
other also they fall within the prediction ellipse of the control groups. Whereas G6 (H
SF) showed no variance on PC1 compared to the nearest control groups while a small
variance could be seen on PC2 implying an overall small variance.
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Figure 3: Heatmap of gene expression profiles for all the groups. Hierarchical cluster
analysis represents the mean of the triplicate for each group. Raw were centered and
unit variance scaling was applied. Groups were clustered by maximum distance and
complete linkage. Expression levels are coloured red for high expression and grey for
low expression.
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Figure 4: Principle component analysis (2D) plot. Each mark represents the mean of
the triplicate for each group. Pareto scaling were applied to rows and SVD with
imputation was used to calculate principal components. PC1 and PC2 explain 59% and
16.7% of the total variance, respectively along with 95% of prediction ellipses.

3.3 Differential gene expression analysis
Differentially expressed genes (DEGs) were obtained for the following
experimental groups, G6 (H SF), G7 (H SB) and G8 (H SF SB). To define DEGs, a
threshold was set on two categories, 0.05 false discovery rate (FDR), which was
calculated based on p value using the Benjamini-Hochberg method and log 2 (fold
change). Firstly, a total of 830 genes were differentially expressed in G6 (H SF) where
484 genes were up regulated and 346 genes were down regulated. Secondly, a total of
733 genes were differentially expressed in G7 (H SB) where 486 genes were up
regulated and 247 genes were down regulated. Lastly, a total of 401 genes were
differentially expressed in G8 (H SF SB) where 285 genes were up regulated and 116
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genes were down regulated. A volcano plot is used as visualization for the fold change
compared to the usual statistical significance of p values for each of the three
experimental groups instead of FDR (Fig. 5A-C). Top 5 up regulated and down
regulated DEGs of these groups are shown in (Table 3) and (Table 4), respectively.
DEGs were found to be uniquely expressed within each respective group as well as
other common genes were found overlapping between the three experimental groups.
DEGs with total of 138 genes were up regulated between the three experimental groups
while total of 47 genes were down regulated (Fig. 5D-E).

Figure 5: Differential gene expression analysis. (A-C) Volcano plot for DEGs for
each of the three experimental groups (A) G6 (H SF). (B) G7 (H SB). (C) G8 (H SF
SB). Illustrating log2 (fold change) against statistical significance of –log10 (p
values). (D-E) Venn diagrams of DEGs of the three experimental groups. (D)
Distribution of the up regulated DEGs. (E) Distribution of the down regulated
DEGs.
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Table 3: Top up regulated DEGs in the three experimental groups
Description

Fold
change

FDR

Cyp2b2

Cytochrome P450, family 2,
subfamily b, polypeptide 2

12.80434

3.59E-30

Cyp2b1

Cytochrome P450, family 2,
subfamily b, polypeptide 1

12.10023

1.80E-31

Ces2a

Carboxylesterase 2A

6.758936

2.96E-22

Vnn1

Vanin 1

5.862473

3.18E-06

Acaa2

Acetyl-coa acyltransferase 2

5.01974

2.33E-11

9.202453

3.68E-11

Gene ID

Expected Function

G6 (H SF)

G7 (H SB)
Cpa1
Carboxypeptidase A1
Aldh3a1

Aldehyde dehydrogenase 3
family, member A1

8.399899

9.81E-19

Akr1b8

Aldo-keto reductase family
1, member B8

6.098191

3.06E-12

Nefl

Slc10a4

Neurofilament, light
polypeptide
Solute carrier family 10,
member 4

5.641934

3.37E-06

4.828877

0.000127

Aging; drug metabolic
process; nicotine metabolic
process
Drug metabolic process;
response to calcium ion;
response to drug
Retinoid metabolic process
Acute inflammatory response
; cell-cell adhesion; chronic
inflammatory response
Acetyl-coa metabolic process;
fatty acid beta-oxidation;
cellular response to hypoxia
Proteolysis
Aging; positive regulation of
cell proliferation; response to
camp
Oxidation-reduction process
Cerebral cortex development;
hippocampus development;
intermediate filament
polymerization or
depolymerization
Adult behavior; response to
drug

G8 (H SF SB)
Drug metabolic process;
response to calcium ion;
response to drug
Aging; drug metabolic
process; nicotine metabolic
process

Cyp2b1

Cytochrome P450, family 2,
subfamily b, polypeptide 1

11.55794

9.21E-30

Cyp2b2

Cytochrome P450, family 2,
subfamily b, polypeptide 2

10.36073

9.21E-30

4.650745

1.61E-18

Oxidation-reduction process

4.281811

0.000209

3.832358

1.51E-08

Proteolysis
Acetyl-coa metabolic process;
fatty acid beta-oxidation;
cellular response to hypoxia

Cpa1

Aldo-keto reductase family
1, member B8
Carboxypeptidase A1

Acaa2

Acetyl-coa acyltransferase 2

Akr1b8

26
Table 4: Top down regulated DEGs in the three experimental groups
Gene ID

Description

Fold
change

FDR

Expected Function

-4.64973

0.000397

Circadian rhythm; positive
regulation of circadian rhythm;
positive regulation of transcription
by RNA polymerase II

-4.34139

0.002859

Unkown

-4.32149

0.001026

Cellular response to dopamine;
response to cisplatin; potassium
ion transmembrane transport

-4.2387

7.08E-07

Circadian regulation of gene
expression; circadian rhythm;

-4.20382

3.88E-05

Reactive oxygen species
metabolic process

G6 (H SF)
Arntl2

LOC102549948

Hcn3

Npas2
ND2

Aryl hydrocarbon
receptor nuclear
translocator-like 2
Uncharacterized
LOC102549948
Hyperpolarizationactivated cyclic
nucleotide-gated
potassium channel 3
Neuronal PAS
domain protein 2
NADH
dehydrogenase
subunit 2

G7 (H SB)
Negative regulation by host of
viral exo-alpha-sialidase activity;
negative regulation by host of
viral glycoprotein metabolic
process
Aging; cellular response to
hormone stimulus; conditioned
taste aversion
Adult behavior; negative
regulation of synaptic
transmission; presynaptic active
zone assembly

Ptx3

Pentraxin 3

-6.06793

6.68E-10

Fos

FBJ osteosarcoma
oncogene

-4.86634

1.24E-10

Pcdh17

Protocadherin 17

-4.71013

1.53E-06

Opcml

Opioid binding
protein/cell adhesion
molecule-like

-4.36873

0.000109

Cell adhesion

Lrrtm2

Leucine rich repeat
transmembrane
neuronal 2

-4.02803

6.18E-05

Synapse organization; long-term
synaptic potentiation; negative
regulation of receptor
internalization;

Fos

FBJ osteosarcoma
oncogene

-5.8923

1.68E-12

Ptx3

Pentraxin 3

-3.80319

6.69E-06

Inhba

Inhibin beta A
subunit

-3.73907

4.18E-08

Ngp

Neutrophilic granule
protein

-3.59586

0.001207

Tlr12

Toll-like receptor 12

-3.46918

5.02E-05

G8 (H SF SB)
Aging; cellular response to
hormone stimulus; conditioned
taste aversion
Negative regulation by host of
viral exo-alpha-sialidase activity;
negative regulation by host of
viral glycoprotein metabolic
process
Cellular response to cholesterol;
cellular response to folliclestimulating hormone stimulus;
activin receptor signaling pathway
Defense response; negative
regulation of endopeptidase
activity
Signal transduction
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3.4 Gene ontology enrichment analysis
In order to investigate the biological processes associated with DEGs, gene
ontology (GO) enrichment analysis was performed using BiNGO, a known Cytoscape
software plugin. This analysis was carried out on the up regulated and the down
regulated genes for the three experimental groups G6 (H SF), G7 (H SB) and G8 (H
SF SB) in addition to the up regulated and the down regulated common genes
mentioned previously (Table 5).

Table 5: List of relevant GO enrichment analysis
Genes
FDR
number
G6 (H SF) Up regulated
Regulation of
36
2.85E-03
programmed cell death
Response to organic
80
9.15E-14
substance
Term name

Response to stress

71

9.63E-06

G7 (H SB) Up regulated
Response to drug
26
7.92E-04
Response to oxidative
19
1.15E-04
stress
Regulation of cell
2
3.82E-02
projection size
G8 (H SF SB) Up regulated
Response to drug
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4.32E-07

Regulation of lipid
11
1.41E-04
metabolic process
Regulation of tumor
necrosis factor
4
1.33E-02
production
Common genes - Up regulated
Response to drug
Regulation of response
to stress
Inflammatory response

Genes
FDR
number
G6 (H SF) Down regulated

Term name

Cellular respiration

8

2.14E-03

Regulation of
89
2.40E-02
biological process
Negative regulation of
17
2.59E-02
biosynthetic process
G7 (H SB) Down regulated
Electron transport chain

6

2.30E-02

Cellular respiration

5

3.83E-02

Negative regulation of
29
3.72E-02
cellular process
G8 (H SF SB) Down regulated
Regulation of
2
1.96E-02
epinephrine secretion
Cyclooxygenase
2
1.66E-02
pathway
Regulation of
macrophage
2
3.70E-02
differentiation
Common genes - Down regulated
Cyclooxygenase
2
5.57E-03
pathway

12

2.73E-03

7

4.51E-02

Cellular respiration

3

2.06E-02

6

4.51E-02

Electron transport chain

3

2.09E-02
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Some repetitive GO enriched terms can be seen among the different gene sets
most notably: response to drug, response to stress, cellular respiration and electron
transport chain. Moreover, unique GO enriched terms have been found. For example, in G6
(H SF) regulation of programmed cell death, G8 (H SF SB) regulation of tumor necrosis factor
production. And inflammatory response in the common genes.

3.5 Pathway analysis
Next, pathway analysis was explored only in regards to G6 (H SF) as it is the
focus of this study. Pathway analysis were performed using ingenuity pathway analysis
(IPA) software. For more stringent analysis, FDR threshold was changed to 0.01
instead of 0.05, leaving total of 529 DEGs where 308 genes were up regulated and 221
genes were down regulated. The most significant canonical pathways are presented in
(Table 6).

Other canonical pathway of interest presented were oxidative

phosphorylation and unfolded protein response.

Table 6: List of top significant canonical pathway associated with G6 (H SF)
p value

Overlap
percentage

5.13E-07

29.60%

1.94E-06

40%

Mevalonate pathway I

1.16E-05

41.70%

Sirtuin signaling pathway

1.97E-05

8.50%

Mitochondrial
dysfunction

3.32E-05

10.80%

Pathway
Superpathway of
cholesterol biosynthesis
Superpathway of
geranylgeranyl
diphosphate biosynthesis
1 (via mevalonate)

Genes
ACAT2, EBP, FDPS, HADHB, HMGCR,
HMGCS2, MSM01, PMVK
ACAT2, FDPS, HADHB, HMGCR,
HMGCS2, PMVK
ACAT2, HADHB, HMGCR, HMGCS2,
PMVK
ACADL, APP, ATP5F1A, CDH1, CPT1A,
CPT1B, EPAS1, GABARAPL2, GADD45A,
HMGCS2, IDH2,PGK1, SDHC, SLC25A5,
SLC2A1, TIMM17A,
TOMM40L,UQCRFS1, XPC
APP, ATP5F1A, ATP5MC3, ATP5MG,
COX5A, CPT1A,CPT1B, HSD17B10,
PINK1, PRDX3,SDHC, UQCRC1,
UQCRFS1

29
Furthermore, IPA offers toxicity functions linked to the DEGs provided and
manually curated IPA knowledge base supporting clinical pathology endpoints.
Among them “Hepatotoxicity” showed five top enriched toxicity functions which were
liver steatosis, HCC, liver hyperplasia / hyperproliferation, liver cholestasis and liver
damage. Focusing on our target HCC, IPA predicted an inhibition of HCC with p value
of 8.27E-05 and total of 45 genes effecting HCC (Fig. 6). One of these 45 genes,
HMGCR found to be inconsistent with the aim of this analysis while ACOX1 and
CTNNB1 have a direct inhibition relationship. Leaving the rest of 42 genes with
unpredicted effect. These 45 genes were reinvestigated in both hierarchical cluster
analysis as it displayed the 45 gene expression profiles among the other experimental
groups (Fig. 7) and BiNGO for GO enrichment analysis shown in (Table 7).

Figure 6: Inhibition of HCC in G6 (H SF)

30

Figure 7: Heatmap of the 45 genes involved in HCC inhibition. Hierarchical cluster
analysis represents the mean of the triplicate for each group. Raw were centered and
unit variance scaling was applied. Groups were clustered by maximum distance and
complete linkage. Expression levels are coloured red for high expression and grey for
low expression.

Table 7: GO enrichment analysis of the 45 genes involved in HCC inhibition
Genes
number
Up regulated genes
Negative regulation of
2
cell development
Regulation of wound
2
healing
Regulation of response
4
to stress
Term name

FDR

4.77E-02
2.99E-02
2.99E-02

Genes
number
Down regulated genes
Negative regulation of
3
apoptosis
Negative regulation of
3
programmed cell death
Term name

Cell proliferation

2

FDR

2.95E-02
2.95E-02
4.98E-02
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To further pinpoint genes associated with relevance biological functions to the
HCC, these 45 genes were re-analyzed through IPA. Within the different functions
provided, two functions standout from the rest which were incidence of malignant
tumor and angiogenesis of tumor, both of which were decreased with p value of 7.49E06 and 1.10E-05, respectively. Total of 8 genes involved even though one of these
genes, KDR showed inconsistency while three genes IQGAP1, KRAS and BRAF
showed unpredicted effect (Fig. 8).

Figure 8: Incidence of malignant tumor and angiogenesis decline in G6 (H SF)

3.6 String network analysis
String network analysis provides an insight over the diverse interactions
among the expressed proteins of interest. Theses interactions included the following:
databases, experiments, gene neighborhood, gene fusion, gene co-occurrence, coexpression, text-mining and protein homology. The higher the number of association
dedicated to a certain node or hub, the higher the importance it projects. Hence, the 45
genes involved in HCC inhibition and the 8 genes involved in incidence of malignant
tumor and angiogenesis of tumor were examined for string network analysis (Fig. 9)
and (Fig. 10) respectively.
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Figure 9: Network analysis of 45 proteins involved in HCC inhibition. The edges
represents different protein-protein interaction colour coded; blue- curated databases,
pink-experimentally determined, yellow- textmining, black- coexpression.
Disconnected node were hidden.

Figure 10: Network analysis of 8 proteins of interest. The edges represents different
protein-protein interaction colour coded; blue- curated databases, pink-experimentally
determined, yellow- textmining, black- coexpression.
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3.7 qPCR quantification and validation
Finally, a validation through qPCR is needed for the accuracy and
reproducibility of gene expression results produced by RNA sequencing data. Five
random DEGs were chosen from G6 (H SF) which were BTG1, PAWR, BMP4,
DNAJB9 and CIDEA. The transcript level of these 5 genes were differently expressed
and showed the same overall expression pattern (Fig. 11).
At first both GAPDH and ACTB were chosen as reference genes however, both
were up regulated, GAPDH was up regulated by 3.9 folds change while ACTB was up
regulated by 7 fold change. Eventually, 18s rRNA was tested and shown a consistent
expression hence was chosen as reference gene for qPCR data normalization.

Figure 11: qPCR validation of five DEGs normalized against 18s rRNA
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Chapter 4: Discussion

With the ongoing search for an effective anti-cancer drug to tame down HCC
aggressiveness and prolong its associated survival comes the need to characterize and
define the underlying mechanisms of action. For once, the anti-cancer activity of
saffron constituent, safranal, is widely known, yet, the precise mechanism still not fully
understood. Identification of specific genes that mediate an inhibitory reaction toward
HCC will improve the available conventional therapies and might introduce safranal
as a novel natural-based chemotherapeutic agent.
In this study, a transcriptomic approach was used to assess safaranl’s
therapeutic effect in DEN-induced HCC in vivo model. Two methodologies of
dimension reduction, hierarchical cluster analysis and PCA were used to obtain an
overall view on RNA sequencing data. G5 (H) have shown the expected change in
gene expression profile and major variance compared to the other groups. Excitingly,
G6 (H SF) have shown similar gene expression profile to control group G1 (C W)
resulting in similar clustering. Additionally, G6 (H SF) showed smaller variance when
compared to other control groups (G3 (C SB) and G4 (C SF SB)).
Several studies invoke the cellular response of sorafenib that not only involve
receptor tyrosine kinase (RTKs) signaling but extend it to mitochondrial quality
control pathways that collectively lead to cancer suppression (Will et al., 2008; Coriat
et al., 2012; Zhang et al., 2017). Sorafenib can induce the production of mitochondrial
reactive oxygen species (mROS), although ROS are essential for cancer prosperity yet
elevated level of extended ROS production can introduce cellular damage to the point
where cell death becomes inevitable. Quite conveniently, cancer cells are extremely
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sensitive to ROS induced by drugs (Chiou et al., 2009). In the present study, biological
processes such as response to drug, response to stress, regulation of response to stress,
response to oxidative stress, cellular respiration and electron transport chain have been
consistently identified upon GO enrichment analysis on DEGs among the three
experimental group G6 (H SF), G7 (H SB), G8 (H SF SB) and the common genes
between them. This implies the fact that both safranal and sorafenib anti-cancer
activities modulate mitochondrial quality control pathways.
As the focus of this study is G6 (H SF), pathway analysis was mapped to DEGs
of G6 (H SF). Top three canonical pathways were interconnected metabolomic
pathways including superpathway of cholesterol biosynthesis, superpathway of
geranylgeranyl diphosphate biosynthesis I and mevalonate pathway I. Evidence to link
between cancer and metabolomic pathways had emerged and now metabolomics
alteration is considered among the hallmarks of cancer (Hanahan and Weinberg, 2011;
Pavlova and Thompson, 2016). The constant need of cancer to grow and proliferate
require an altered metabolic pathways that can meet its demands (Muñoz-Pinedo et al.,
2012). Some even raise the question if cancer after all is another metablomic disease
(Coller, 2014). Intriguingly, cancer metabolism can be viewed as the classic response
of drug resistance (Rahman and Hasan, 2015).
Revisiting the top up regulated DEGs of G6 (H SF), CYP2B1 and CYP2B2
were found, both of which come from cytochromes P450 (P450s) family. P450s
enzymes catalyze the metabolism of either endogenous substrates like steroids, fatty
acids, and fat soluble vitamins or exogenous substrates like drugs and pesticides
(Harleton, 2004). Enzymes from CYP2B family are involved in drug metabolism and
xenobiotics (Schoedel and Tyndale, 2003). Hence, the action of metabolism of an anti-
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cancer drug by P450s enzymes may deactivate the cytotoxic activities of that drug. On
the other hand, several prodrugs can be activated by P450s enzymes where prodrugs
are needed to be metabolized first before exhibiting the active cytotoxic form
(McFadyen et al., 2004). The evident overexpression of CYP2B1 and CYP2B2 may
increase the breakdown of safranal and hence its secretion. Therefore, the optimal
effects of safranal might not be seen due to loss of maintaining the proper level of the
drug within the body. This might serve as a mechanism for drug tolerance. It is worth
mentioning that even popular therapeutic agents are subjected to such response. For
instance, paclitaxel used for ovarian, breast and non-small cell lung cancer is
metabolized by CYP2C8 and CYP3A into deactivated form. Doxorubicin used for
sarcoma, breast and ovarian cancer is metabolized by CYP3A4 into deactivated form.
Cyclophosphamide used for sarcoma, breast and ovarian cancer is metabolized by
CYP2B6 and CYP3A4 into activated form reflecting on the fact that
cyclophosphamide is prodrug. (Kivisto et al., 1995). And since the prediction behind
P450s enzymes metabolic pathway either drug activation or deactivation is not clear
as it might increase the intrinsic pharmacodynamics activity of the drug or just simply
deactivate the drug and facilitate its clearance from the body (Furge and Guengerich,
2006). It is also conceivable that safranal’s metabolite/s, rather than its intact version,
is the major contributor to the drug’s potent anti-cancer effect.
Sirtuin signaling pathway was the fourth canonical pathway displayed. Cellular
redox changes occurring due to oxidative, metabolic or genotoxic stress are detected
and an adequate response is directed by sirtuin proteins. For instance, SIRT1, stress
sensor, in stress condition it implement cell survival and drive the cell in cytoprotective
manner but in extreme stress condition it leads the cell to apoptosis (Raynes et al.,
2013). Evidence have compiled over the dual functionality of sirtuin when it comes to
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carcinogenesis (Bosch-Presegue and Vaquero, 2011; O'Callaghan and Vassilopoulos,
2017). Although none of the sirtuin proteins family have been significantly detected
in sirtuin signaling pathway, 9 out of 19 genes found in sirtuin signaling pathway were
involved in cell death of tumor cells based on IPA ingenuity knowledge base.
Mitochondrial dysfunction was the fifth canonical pathway observed.
Mitochondrial dysfunction is greatly associated with cancer development and cancer
metastatic potential (Chen, 2012; Hsu et al. 2016). However, contradicting data often
resurface. To illustrate, various alterations in cellular redox state, respiratory chain
complexes and mitochondrial functional parameters, induced oxidative stress and ROS
production are all consequences of doxorubicin treatment that triggers mitochondriamediated apoptosis (Kuznetsov et al., 2011). Similar scenario may describe safranal
anti-cancer activity. In fact, safranal correlates impeccably with the previous GO
enrichment analysis. 6 out of 13 genes found in mitochondrial dysfunction were
involved in cell death of tumor cells based on IPA ingenuity knowledge base. Not to
mention, oxidative phosphorylation was found within the canonical pathways
indicating ROS production.
Unfolding protein response is another appealing canonical pathway existed in
pathway analysis. With the up regulation of DNAJB9, EDEM1 and PDIA6 all of which
indicate endoplasmic reticulum (ER) stress (Shen et al., 2002; Olivari and Molinari,
2007; Vekich et al., 2012). It has been reported that, if ER stress prolong and remain
unresolved this might trigger autophagy and eventually leading to cell death (Luo and
Lee, 2012).
Primarily, 45 genes were found to be involved in HCC inhibition however,
most of their involvements were labelled as unpredicted effect. Therefore, in the
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interest of more conclusive findings, theses 45 genes were re-analysed. In comparison
to other experimental groups, gene expression pattern showed a clear difference in the
expression of these 45 genes implying the specificity of these genes to G6 (H SF). In
addition to that, GO term enrichment revealed important biological processes
empathizing on the decline in cell development, regulation of wound healing, decrease
in cell proliferation and the negative regulation of both apoptosis and programmed cell
death was declined.
The re-analysis of these 45 genes reinforced the inhibition of two functions of
interest; incidence of malignant tumor and angiogenesis. Genes involved in the
decrease of incidence of malignant tumor were ACOX1, CTNNB1 and CDH1 whereas
genes involved in the decrease of angiogenesis of tumor were BRAF, CDH1 and
SERPINC1. The rest of IQGAP1, KARS and BRAF shared unpredicted effect while
KDR showed inconsistent relationship.
Acyl-CoA oxidase 1 (ACOX1), is a rate-limiting enzyme of the peroxisomal
fatty acid β-oxidation pathway of very long chain fatty acids (VLCFAs) (Vluggens et
al., 2010). It has been established that deficient ACOX1 resulted in accumulation of
VLCFAs and led to growth retardation, microvesicular steatohepatitis, apoptosis, liver
regeneration, oxidative stress and ultimately HCC development (Huang et al., 2011).
Catenin beta 1 (CTNNB1) is a cell surface cadherin protein complex subunit
utilized as intracellular signal transducer in WNT signaling pathway; dysregulation in
its activity has been strongly related to HCC progression (Monga, 2015).
Unexpectedly, CTNNB1 has recently been introduced as tumor suppressive where KO
mice experienced an intense HCC development after DEN treatment (Zhang et al.,
2010) while another study documented the same results after DEN and phenobarbital
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treatment (Rignall et al., 2010). E-cadherin (CDH1) is transmembrane glycoprotein
within the cadherins family essential for cell-cell adhesion in calcium dependent
manner. Vital E-cadherin is a calcium-dependent cell-cell adhesion molecule playing
a crucial in epithelial architecture establishment and cell polarity and differentiation
maintenance (Liu and Chu, 2014). CDH1 has been recognized as tumor suppressor in
number of cancers including lobular breast cancer, diffuse gastric carcinoma, ovarian
cancer and colorectal carcinoma (Schrader et al., 2007; Kim et al., 2016; Wang et al.,
2016). CDH1 role in HCC was inconclusive and was thought early on to promote HCC
growth (Wei, 2002). However, more recent accumulated evidence confirmed CDH1
role in suppressing liver carcinogenesis (Nakagawa et al., 2014; Schneider et al., 2014;
Zhu et al., 2017). CDH1 is also interestingly involved in binding and regulating
CTNNB1 thus mediating growth suppression (Gottardi et al., 2001).
Serpin family C member 1 (SERPINC1) is type of serine proteinase inhibitors
also known as antithrombin, it prevents coagulation factors IX and X (Heit et al.,
2013). Its deficiency is associated with several diseases including liver cirrhosis, liver
cancer, nephropathy and disseminated intravascular coagulation (DIC) (Lu et al.,
2017). SERPINC1 was described to effectively inhibit tumor angiogenesis in a mouse
fibrosarcoma model (Larsson et al., 2000). However, its exact role in HCC is not well
explored.
Mitogen-activated protein kinase (MAPK) pathway consist of series of
serine/threonine kinases which convey intracellular signals from extracellular
molecules such as growth factors, differentiation factors, hormones and tumorpromoting substance for cell proliferation, differentiation and survival purposes.
Mainly, RAS, RAF, MEK and ERK are the key protein kinases in this pathway (Yang
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and Liu, 2017). It has been found that 30% of cancers bar an activated RAS/RAF/MEK
signaling cascade (Zhang et al., 2011). Thereby, a collective preclinical and clinical
evidence compiled on irregular activation of Ras/Raf/MEK/ERK signaling pathway in
HCC (Yang and Liu, 2017). Notably, blocking or inhibiting Ras/Raf/MEK/ERK
signaling pathway has exhibited several anti-cancer activities (Li et al., 2016). In the
present study, KRAS, a member of RAS family and BRAF, a member of RAF family,
were significantly down regulated upon safranal treatment and were associated with
decrease of angiogenesis and tumor incidence.
Finally and through string network analysis, regulatory hubs were identified
based on the number of connections to other components in the same network. First
network analysis of 45 genes involved in HCC inhibition, KRAS and CTNNB1 were
recognized as regulatory hubs and similar outcome is drawn from the network analysis
of 8 genes of interest. In addition to IQGAP1 which is strongly associated to HCC
progression and can be used as HCC biomarker (Xia et al., 2014).
Taken together, this study has assessed safranal’s anti-cancer properties on
DEN induced HCC model through a transcriptomic analysis. Such analysis
demonstrated a unique gene expression profile of safranal treated group and
investigated associated biological processes and correlated canonical pathways in such
a therapeutically treated animals. Current study, revealed key genes associated with
HCC inhibition and explored further to attain their value as therapeutic candidates
upon safranal treatment.
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Chapter 5: Conclusion
In conclusion, transcriptomic analysis herein clearly indicated the therapeutic
effects of safranal against HCC in vivo model. Although signs of drug tolerance was
shown still that did not devalue its substantial anti-cancer effects. This study
demonstrated safranal’s involvement in mitochondrial dysfunction, induced oxidative
stress and increased ROS production and ultimately leading to cell death. Moreover,
safranal

caused

disruption

of

the

HCC

activated

MAPK

pathway

or

Ras/Raf/MEK/ERK signaling pathway which in turns effects cell proliferation,
differentiation and survival.
Transcriptomic analysis using RNA sequence provides huge data to process
yet it only offers one side of the story. The assumption that RNA transcripts
corresponds perfectly to the expression of proteins generated is not always true. That
is largely due to post-translational modifications. Hence, a proteomic study should
follow up to deliver further insights into protein expression and interaction.
Given the growing realization on the fact that single anti-cancer agent may not
be as successful combating cancer, combination therapy seems to hold captivating
qualities evading drug resistance and expansion of drug synergy effects. Further
studies are currently underway to investigate the synergistic properties of safranal and
sorafenib.
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